The Effect of Ginger (Zingiber officinalis) and Artichoke (Cynara cardunculus) Extract Supplementation on Functional Dyspepsia: A Randomised, Double-Blind, and Placebo-Controlled Clinical Trial

Attilio Giacosa, Davide Guido, Mario Grassi, Antonella Riva, Paolo Morazzoni, Ezio Bombardelli, Simone Perna, Milena A Faliva, Mariangela Rondanelli, Attilio Giacosa, Davide Guido, Mario Grassi, Antonella Riva, Paolo Morazzoni, Ezio Bombardelli, Simone Perna, Milena A Faliva, Mariangela Rondanelli

Abstract

Objective. Functional dyspepsia (FD) is a frequent clinical finding in western world. The aim of this study is to compare the efficacy of a ginger and artichoke supplementation versus placebo in the treatment of FD. Methods. A prospective multicentre, double blind, randomized, placebo controlled, parallel-group comparison of the supplement and placebo over a period of 4 weeks was performed. Two capsules/day were supplied (before lunch and dinner) to 126 FD patients (supplementation/placebo: 65/61). Results. After 14 days of treatment, only supplementation group (SG) showed a significant amelioration (SG: α S = +1.195 MCA score units (u), P = 0.017; placebo: α P = +0.347 u, P = 0.513). The intercept (α) resulted to be significantly higher in SG than in placebo (α S - α P = +0.848 u, P < 0.001). At the end of the study, the advantage of SG versus placebo persists without variation (β S - β P = +0.077 u, P = 0.542). In SG, a significant advantage is observed for nausea (β S - β P = -0.398 u, P < 0.001), epigastric fullness (β S - β P = -0.241, P < 0.001), epigastric pain (β S - β P = -0.173 u, P = 0.002), and bloating (β S - β P = -0.167 u, P = 0.017). Conclusions. The association between ginger and artichoke leaf extracts appears safe and efficacious in the treatment of FD and could represent a promising treatment for this disease.

Figures

Figure 1
Figure 1
Flow diagram of a trial of supplementation with a combination of two highly standardized extracts from Zingiber officinale and Cynara cardunculus in the treatment of functional dyspepsia. The diagram includes the number of patients analyzed for the main outcome (effect on functional dyspepsia).
Figure 2
Figure 2
Trend of secondary outcomes.

References

    1. Camilleri M., Dubois D., Coulie B., et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US upper gastrointestinal study. Clinical Gastroenterology and Hepatology. 2005;3(6):543–552. doi: 10.1016/s1542-3565(05)00153-9.
    1. Knill R. P., Jones R. P. Geografical differences in the prevalence of dyspepsia. Scandinavian Journal of Gastroenterology. 1991;26:17–24.
    1. Talley N. J., Zinsmeister A. R., Schleck C. D., Melton L. J., III Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology. 1992;102(4):1259–1268.
    1. Holtmann G. E. H., Goebell H., Talley N. J. Dyspepsia in consulters and non-consulters: prevalence, health-care seeking behaviour and risk factors. European Journal of Gastroenterology and Hepatology. 1994;6(10):917–924. doi: 10.1097/00042737-199410000-00014.
    1. Talley N. J., Stanghellini V., Heading R. C., Koch K. L., Malagelada J. R., Tytgat G. N. Functional gastroduodenal disorders. Gut. 1999;45(2):1137–1142.
    1. Ford A. C., Bercik P., Morgan D. G., Bolino C., Pintos-Sanchez M. I., Moayyedi P. The Rome III criteria for the diagnosis of functional dyspepsia in secondary care are not superior to previous definitions. Gastroenterology. 2014;146(4):932–940. doi: 10.1053/j.gastro.2014.01.014.
    1. Mahadeva S., Goh K. L. Epidemiology of dyspepsia: a global perspective. World Journal of Gastroenterology. 2006;12(17):2661–2666.
    1. Haag S., Talley N. J., Holtmann G. Symptom patterns in functional dyspepsia and irritable bowel syndrome: relationship to disturbances in gastric emptying and response to a nutrient challenge in consulters and non-consulters. Gut. 2004;53(10):1445–1451. doi: 10.1136/gut.2003.030049.
    1. Stanghellini V., de Ponti F., de Giorgio R., Barbara G., Tosetti C., Corinaldesi R. New developments in the treatment of functional dyspepsia. Drugs. 2003;63(9):869–892. doi: 10.2165/00003495-200363090-00003.
    1. Talley N. J. Dyspepsia: management guidelines for the millennium. Gut. 2002;50(4):iv72–iv78.
    1. Micklefield G. H., Redeker Y., Meister V., Jung O., Greving I., May B. Effects of ginger on gastroduodenal motility. International Journal of Clinical Pharmacology and Therapeutics. 1999;37(7):341–346.
    1. Ernst E., Pittler M. H. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. British Journal of Anaesthesia. 2000;84(3):367–371. doi: 10.1093/oxfordjournals.bja.a013442.
    1. Holtmann G., Adam B., Haag S., Collet W., Grünewald E., Windeck T. Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind, multicentre trial. Alimentary Pharmacology & Therapeutics. 2003;18(11-12):1099–1105. doi: 10.1046/j.1365-2036.2003.01767.x.
    1. Talley N. J., Colin-Jones D., Koch K. L., et al. Functional dyspepsia. A classification with guidelines for diagnosis and management. Gastroenterology International. 1991;4:145–160.
    1. Talley N. J., Haque M., Wyeth J. W., et al. Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. Alimentary Pharmacology & Therapeutics. 1999;13(2):225–235. doi: 10.1046/j.1365-2036.1999.00445.x.
    1. World Medical Association. World Medical Association Declaration of Helsinki. Ethical Principles of Medical Research Involving Human Subjects (2013 revision) Ferney-Voltaire, France: World Medical Association; 2004.
    1. Likert R. A technique for the measurement of attitudes. Archives of Psychology. 1932;140:1–55.
    1. Lohelin J. C. Latent Variable Models: An Introduction to Factor, Path and Structural Equation Analysis. New York, NY, USA: Lawrence Erlbaum Associates; 2004.
    1. Mair P., de Leeuw J. A general framework for multivariate analysis with optimal scaling: the R package aspect. Journal of Statistical Software. 2010;32(9):1–23.
    1. Bagozzi R. P., Yi Y. Specification, evaluation, and interpretation of structural equation models. Journal of the Academy of Marketing Science. 2012;40(1):8–34. doi: 10.1007/s11747-011-0278-x.
    1. Rosseel Y. Lavaan: an R package for structural equation modeling. Journal of Statistical Software. 2012;48(2):1–36.
    1. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
    1. Dobrilla G., Comberlato M., Steele A., Vallaperta P. Drug treatment of functional dyspepsia. A meta-analysis of randomized controlled clinical trials. Journal of Clinical Gastroenterology. 1989;11(2):169–177. doi: 10.1097/00004836-198904000-00011.
    1. Futagami S., Shimpuku M., Yin Y., et al. Pathophysiology of functional dyspepsia. Journal of Nippon Medical School. 2011;78(5):280–285. doi: 10.1272/jnms.78.280.
    1. Committee on Herbal Medicinal Products. Assessment report on Zingiber officinale Roscoe, rhizome. European Medicines Agency. 2011;(EMA/HMPC/577856/2010)
    1. Wu K.-L., Rayner C. K., Chuah S.-K., et al. Effects of ginger on gastric emptying and motility in healthy humans. European Journal of Gastroenterology & Hepatology. 2008;20(5):436–440. doi: 10.1097/meg.0b013e3282f4b224.
    1. Ali B. H., Blunden G., Tanira M. O., Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food and Chemical Toxicology. 2008;46(2):409–420. doi: 10.1016/j.fct.2007.09.085.
    1. Gebhardt R., Fausel M. Antioxidant and hepatoprotective effects of artichoke extracts and constituents in cultured rat hepatocytes. Toxicology in Vitro. 1997;11(5):669–672. doi: 10.1016/s0887-2333(97)00078-7.
    1. Gebhardt R. Inhibition of hepatic cholesterol biosynthesis by artichoke leaf extracts is mainly due to luteolin. Cell Biology and Toxicology. 1997;13:p. 58.
    1. Brown J. E., Rice-Evans C. A. Luteolin-rich artichoke extract protects low density lipoprotein from oxidation in vitro . Free Radical Research. 1998;29(3):247–255. doi: 10.1080/10715769800300281.
    1. Pérez-García F., Adzet T., Cañigueral S. Activity of artichoke leaf extract on reactive oxygen species in human leukocytes. Free Radical Research. 2000;33(5):661–665. doi: 10.1080/10715760000301171.
    1. Rechner A. R., Pannala A. S., Rice-Evans C. A. Caffeic acid derivatives in artichoke extract are metabolised to phenolic acids in vivo. Free Radical Research. 2001;35(2):195–202. doi: 10.1080/10715760100300741.
    1. Ishida K., Kojima R., Tsuboi M., Tsuda Y., Ito M. Effects of artichoke leaf extract on acute gastric mucosal injury in rats. Biological and Pharmaceutical Bulletin. 2010;33(2):223–229. doi: 10.1248/bpb.33.223.
    1. Emendörfer F., Bellato F., Noldin V. F., et al. Antispasmodic activity of fractions and cynaropicrin from Cynara scolymus on guinea-pig ileum. Biological and Pharmaceutical Bulletin. 2005;28(5):902–904. doi: 10.1248/bpb.28.902.
    1. Ding M., Leach M., Bradley H. The effectiveness and safety of ginger for pregnancy-induced nausea and vomiting: a systematic review. Women and Birth. 2013;26(1):e26–e30. doi: 10.1016/j.wombi.2012.08.001.
    1. Ryan J. L., Heckler C. E., Roscoe J. A., et al. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Supportive Care in Cancer. 2012;20(7):1479–1489. doi: 10.1007/s00520-011-1236-3.
    1. Thomson M., Corbin R., Leung L. Effects of ginger for nausea and vomiting in early pregnancy: a meta-analysis. Journal of the American Board of Family Medicine. 2014;27(1):115–122. doi: 10.3122/jabfm.2014.01.130167.
    1. Kirchhoff R., Beckers C., Kirchhoff G., Trinczek-Gärtner H., Petrowicz O., Reimann H. Increase in choleresis by means of artichoke extract. Results of a randomized placebo-controlled double blind study. Phytomedicine. 1994;1(2):107–115. doi: 10.1016/s0944-7113(11)80027-9.
    1. Aggarwal A., Bhatt M. Commonly used gastrointestinal drugs. Handbook of Clinical Neurology. 2014;120:633–643. doi: 10.1016/b978-0-7020-4087-0.00043-7.
    1. van Roeden S. E., Belle-van Meerkerk G., van Tuyl S. A. C., van De Ree M. A., Muller A. F. Domperidone and the risk of sudden cardiac death. Nederlands Tijdschrift voor Geneeskunde. 2013;157(46)A6770
    1. Hondeghem L. M. Domperidone: limited benefits with significant risk for sudden cardiac death. Journal of Cardiovascular Pharmacology. 2013;61(3):218–225. doi: 10.1097/fjc.0b013e31827afd0d.
    1. Michaud V., Turgeon J. Domperidone and sudden cardiac death: how much longer should we wait? Journal of Cardiovascular Pharmacology. 2013;61(3):215–217. doi: 10.1097/fjc.0b013e31827e2573.
    1. Kanji S., Stevenson A., Hutton B. Sudden cardiac death and ventricular arrhythmias associated with domperidone: evidence supporting health Canada’s warning. The Canadian Journal of Hospital Pharmacy. 2014;67(4):311–312. doi: 10.4212/cjhp.v67i4.1378.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅